article Open AccessTop 10% cited

Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer

British Journal of Cancer · 2012 · Vol. 107(10) · pp. 1776–1782

Victor Abkevich✉(Myriad Genetics)Kirsten M. Timms(Myriad Genetics)Bryan T. Hennessy(Beaumont Hospital)Jennifer Potter(Myriad Genetics)Mark Carey(University of British Columbia)Lisa Meyer(The University of Texas at Austin)Karen Smith‐McCune(University of California, San Francisco)Russell Broaddus(The University of Texas MD Anderson Cancer Center)K.H. Lu(The University of Texas MD Anderson Cancer Center)J Chen(Myriad Genetics)Thuan Van Tran(Myriad Genetics)Deniece R. Williams(Myriad Genetics)Diana Iliev(Myriad Genetics)Srikanth Jammulapati(Myriad Genetics)Liesel M. FitzGerald(Myriad Genetics)Thomas C. Krivak(University of Pittsburgh)Julie A. DeLoia(George Washington University)Alexander Gutin(Myriad Genetics)Gordon B. Mills(University of British Columbia)J. S. Lanchbury(Myriad Genetics)

View via DOI Full-text PDF

Abstract

The HRD score appears capable of detecting homologous recombination defects regardless of aetiology or mechanism. This score could facilitate the use of PARP inhibitors and platinum in breast, ovarian, and other cancers.

PARP inhibition in cancer therapy DNA Repair Mechanisms CRISPR and Genetic EngineeringLoss of heterozygosityHomologous recombinationOvarian cancerBiologyHomologous chromosomeCancer researchBreast cancerDNA repairBRCA2 ProteinGenome instability

MeSH terms

Carcinoma, Ovarian EpithelialAdultAgedAged, 80 and overDNA-Binding ProteinsFemaleHumansMiddle AgedNeoplasms, Glandular and EpithelialOvarian NeoplasmsCohort StudiesDisease-Free SurvivalBRCA1 ProteinLoss of HeterozygosityBRCA2 Protein